The Siemens partnership de-risks the Phase 3 trial supply chain and validates RAD101's potential. Traders should monitor upcoming topline Phase 2b data in 1H 2026 and progression into Phase 3 as key catalysts. Positive data could drive valuation higher given the large unmet need in brain metastases (300,000 U.S. diagnoses annually).
Price Chart
Executive Summary
Radiopharm Theranostics announced a clinical supply agreement with Siemens Healthineers for RAD101, a novel imaging agent targeting brain metastases. The partnership ensures supply for the upcoming Phase 3 registrational trial in the U.S., following positive interim Phase 2b data showing 90% concordance with MRI and FDA Fast Track Designation.
Key Facts
- Radiopharm Theranostics (RAD) and Siemens Healthineers signed a clinical supply agreement for RAD101 in the U.S.
- RAD101 is a novel FASN-targeting PET imaging agent for suspected recurrent brain metastases.
- Interim Phase 2b data showed 90% concordance (primary endpoint) between RAD101 PET imaging and MRI, with significant and selective tumor uptake in brain metastases.
- FDA has granted Fast Track Designation for RAD101 to distinguish between recurrent disease and treatment effect in brain metastases.
- Siemens will radiolabel and distribute 18F-labeled RAD101 to support Radiopharm's upcoming Phase 3 registrational trial in the U.S.
- Company is listed on ASX (RAD) and NASDAQ (RADX).
Financial Impact
Positive advancement in clinical development with no immediate direct financial impact disclosed; reduces execution risk for Phase 3 trial through established manufacturing and distribution partnership.
Risk Factors
- Phase 2b topline data not yet fully reported; interim analysis showed positive trend but final results may differ.
- Phase 3 trial has not yet commenced; regulatory or enrollment delays possible.
- RAD101 remains investigational; future clinical results may not confirm initial promise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-040690 |
| Document: ea028536301ex99-1.htm | 0001213900-26-040690 |
| Document: 0001213900-26-040690-index-headers.html | 0001213900-26-040690 |
| Document: 0001213900-26-040690-index.html | 0001213900-26-040690 |
| Document: 0001213900-26-040690.txt | 0001213900-26-040690 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −52.50% | $0.006660 (−66.70%) |
May 6, 2026 24w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −53.83% | $0.006660 (−66.70%) |
Apr 23, 2026 26w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −55.02% | $0.006660 (−66.70%) |
Apr 16, 2026 27w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −57.05% | $0.006660 (−66.70%) |
Apr 8, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −60.46% | $0.006660 (−66.70%) |
Apr 7, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −63.27% | $0.006660 (−66.70%) |
Apr 1, 2026 29w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −64.16% | $0.006660 (−66.70%) |
Mar 27, 2026 30w ago | 6-K | $0.0200 $0.0200 | · 0.00% | ▼ −16.07% | $0.006660 (−66.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers